115 related articles for article (PubMed ID: 1892771)
1. Abnormally-fucosylated haptoglobin: a cancer marker for tumour burden but not gross liver metastasis.
Thompson S; Cantwell BM; Cornell C; Turner GA
Br J Cancer; 1991 Aug; 64(2):386-90. PubMed ID: 1892771
[TBL] [Abstract][Full Text] [Related]
2. Parallel changes in the blood levels of abnormally-fucosylated haptoglobin and alpha 1,3 fucosyltransferase in relationship to tumour burden: more evidence for a disturbance of fucose metabolism in cancer.
Thompson S; Cantwell BM; Matta KL; Turner GA
Cancer Lett; 1992 Aug; 65(2):115-21. PubMed ID: 1511415
[TBL] [Abstract][Full Text] [Related]
3. Elevated levels of abnormally-fucosylated haptoglobins in cancer sera.
Thompson S; Turner GA
Br J Cancer; 1987 Nov; 56(5):605-10. PubMed ID: 3426924
[TBL] [Abstract][Full Text] [Related]
4. Abnormally-fucosylated serum haptoglobins in patients with inflammatory joint disease.
Thompson S; Kelly CA; Griffiths ID; Turner GA
Clin Chim Acta; 1989 Oct; 184(3):251-8. PubMed ID: 2611998
[TBL] [Abstract][Full Text] [Related]
5. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells.
Narisada M; Kawamoto S; Kuwamoto K; Moriwaki K; Nakagawa T; Matsumoto H; Asahi M; Koyama N; Miyoshi E
Biochem Biophys Res Commun; 2008 Dec; 377(3):792-6. PubMed ID: 18951869
[TBL] [Abstract][Full Text] [Related]
6. Increased fucosylation and other carbohydrate changes in haptoglobin in ovarian cancer.
Thompson S; Dargan E; Turner GA
Cancer Lett; 1992 Sep; 66(1):43-8. PubMed ID: 1451094
[TBL] [Abstract][Full Text] [Related]
7. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures.
Miyoshi E; Nakano M
Proteomics; 2008 Aug; 8(16):3257-62. PubMed ID: 18646007
[TBL] [Abstract][Full Text] [Related]
8. Abnormally fucosylated haptoglobin as a marker for alcoholic liver disease but not excessive alcohol consumption or non-alcoholic liver disease.
Chambers W; Thompson S; Skillen AW; Record CO; Turner GA
Clin Chim Acta; 1993 Oct; 219(1-2):177-82. PubMed ID: 8306457
[No Abstract] [Full Text] [Related]
9. Serum fucosylated haptoglobin in chronic liver diseases as a potential biomarker of hepatocellular carcinoma development.
Asazawa H; Kamada Y; Takeda Y; Takamatsu S; Shinzaki S; Kim Y; Nezu R; Kuzushita N; Mita E; Kato M; Miyoshi E
Clin Chem Lab Med; 2015 Jan; 53(1):95-102. PubMed ID: 25060348
[TBL] [Abstract][Full Text] [Related]
10. A multiwell lectin-binding assay using lotus tetragonolobus for measuring different glycosylated forms of haptoglobin.
Thompson S; Stappenbeck R; Turner GA
Clin Chim Acta; 1989 Apr; 180(3):277-84. PubMed ID: 2743580
[TBL] [Abstract][Full Text] [Related]
11. Site-specific and linkage analyses of fucosylated N-glycans on haptoglobin in sera of patients with various types of cancer: possible implication for the differential diagnosis of cancer.
Takahashi S; Sugiyama T; Shimomura M; Kamada Y; Fujita K; Nonomura N; Miyoshi E; Nakano M
Glycoconj J; 2016 Jun; 33(3):471-82. PubMed ID: 26869352
[TBL] [Abstract][Full Text] [Related]
12. Fucosylated haptoglobin is a novel type of cancer biomarker linked to the prognosis after an operation in colorectal cancer.
Takeda Y; Shinzaki S; Okudo K; Moriwaki K; Murata K; Miyoshi E
Cancer; 2012 Jun; 118(12):3036-43. PubMed ID: 22006099
[TBL] [Abstract][Full Text] [Related]
13. ELISA index of serum fucosylated haptoglobin for diagnosis of HCC using the normal and reverse AAL ELISA.
Shang S; Qin X; Li W; Zhang S; Liu Y
Discov Med; 2016 Jan; 21(113):15-23. PubMed ID: 26896598
[TBL] [Abstract][Full Text] [Related]
14. Haptoglobin phenotype is a critical factor in the use of fucosylated haptoglobin for pancreatic cancer diagnosis.
Morishita K; Ito N; Koda S; Maeda M; Nakayama K; Yoshida K; Takamatsu S; Yamada M; Eguchi H; Kamada Y; Miyoshi E
Clin Chim Acta; 2018 Dec; 487():84-89. PubMed ID: 30189188
[TBL] [Abstract][Full Text] [Related]
15. Serum haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis.
Sun L; Hu S; Yu L; Guo C; Sun L; Yang Z; Qi J; Ran Y
Int J Cancer; 2016 Jun; 138(11):2724-31. PubMed ID: 26756179
[TBL] [Abstract][Full Text] [Related]
16. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers.
Nakano M; Nakagawa T; Ito T; Kitada T; Hijioka T; Kasahara A; Tajiri M; Wada Y; Taniguchi N; Miyoshi E
Int J Cancer; 2008 May; 122(10):2301-9. PubMed ID: 18214858
[TBL] [Abstract][Full Text] [Related]
17. α1-3/4 fucosylation at Asn 241 of β-haptoglobin is a novel marker for colon cancer: a combinatorial approach for development of glycan biomarkers.
Park SY; Lee SH; Kawasaki N; Itoh S; Kang K; Hee Ryu S; Hashii N; Kim JM; Kim JY; Hoe Kim J
Int J Cancer; 2012 May; 130(10):2366-76. PubMed ID: 21780104
[TBL] [Abstract][Full Text] [Related]
18. ESI-LC-MS Method for Haptoglobin Fucosylation Analysis in Hepatocellular Carcinoma and Liver Cirrhosis.
Zhang Y; Zhu J; Yin H; Marrero J; Zhang XX; Lubman DM
J Proteome Res; 2015 Dec; 14(12):5388-95. PubMed ID: 26503433
[TBL] [Abstract][Full Text] [Related]
19. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions.
Kamada Y; Kinoshita N; Tsuchiya Y; Kobayashi K; Fujii H; Terao N; Kamihagi K; Koyama N; Yamada S; Daigo Y; Nakamura Y; Taniguchi N; Miyoshi E
Clin Chim Acta; 2013 Feb; 417():48-53. PubMed ID: 23262369
[TBL] [Abstract][Full Text] [Related]
20. Integrins and haptoglobin: Molecules overexpressed in ovarian cancer.
Villegas-Pineda JC; Garibay-Cerdenares OL; Hernández-Ramírez VI; Gallardo-Rincón D; Cantú de León D; Pérez-Montiel-Gómez MD; Talamás-Rohana P
Pathol Res Pract; 2015 Dec; 211(12):973-81. PubMed ID: 26549463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
